Research field (1)：
Tumor diagnostics and therapeutics
Research theme for competitive and other funds (2)：
2015 - 2017 アリルハイドロカーボン受容体阻害剤による新規癌免疫療法
2015 - 2016 アリルハイドロカーボン受容体阻害剤による新規癌免疫療法
Papers (6)：
Soranobu Ninomiya, Neeharika Narala, Leslie Huye, Shigeki Yagyu, Barbara Savoldo, Gianpietro Dotti, Helen E. Heslop, Malcolm K. Brenner, Cliona M. Rooney, Carlos A. Ramos. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. BLOOD. 2015. 125. 25. 3905-3916
Yuhei Shibata, Takeshi Hara, Senji Kasahara, Toshiki Yamada, Michio Sawada, Ryoko Mabuchi, Takuro Matsumoto, Nobuhiko Nakamura, Hiroshi Nakamura, Soranobu Ninomiya, et al. CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin. HEMATOLOGICAL ONCOLOGY. 2017. 35. 2. 163-171
Takuro Matsumoto, Takeshi Hara, Yuhei Shibata, Nobuhiko Nakamura, Hiroshi Nakamura, Soranobu Ninomiya, Junichi Kitagawa, Nobuhiro Kanemura, Naoe Goto, Yusuke Kito, et al. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemother. Hematological Oncology. 2016
